Poster Abstract Session:
68. Novel Antimicrobial Agents
Friday, October 21, 2011: 12:15 PM-2:15 PM
Room: Poster Hall B1

Learning Objectives:

-

Target Audience: Academicians

Topical Category: A. Antimicrobial agents and Resistance

Tracks: Investigative ID

Presentations:

586
In Vitro Activity of Ceftazidime (CAZ) Combined with Avibactam (NXL104) versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals: CANWARD 2010
Andrew Walkty, MD ; Melanie Baxter, MSc ; Heather J. Adam, PhD ; Kim Nichol, MSc ; Philippe Lagacé-Wiens ; James Karlowsky, PhD ; Daryl J. Hoban, PhD ; George G. Zhanel, PhD

587
Antimicrobial Activity of Ceftaroline/NXL104 Tested Against Contemporary (2010) Clinical Isolates from USA Medical Centers
Helio S. Sader, M.D., Ph.D. ; David J. Farrell, Ph.D. ; Gary J. Moet ; Gregory Williams ; Ronald Jones, MD

588
PMX30063-Clinical and Preclinical Investigations of Transient, Treatment Related Neurosensory Effects
Bozena Korczak, PhD ; Richard Scott, PhD ; Roger Echols, MD ; Joseph Arezzo, PhD

589
Probability of Target Attainment (PTA) of CXA-201 in Patients with Renal Hyperclearance
Benjamin Miller, PharmD ; Mohamad-Samer Mouksassi, PharmD ; Gurudatt Chandorkar, PhD ; Obiamiwe Umeh, MD, MSc

590
The Inoculum Effect and Band-Pass Bacterial Response to Periodic Antibiotic Treatment
Cheemeng Tan, (Co-primary author) ; Robert Smith, (Co-primary author) ; Meta Kuehn ; Lingchong You

591
Combination Topical Agent containing Silver Sulfadiazine,Tetrahydrocurcuminoid and Zinc salts Promotes Wound Healing in Rat Skin Wound model
Paritosh Suman, MBBS ; Hari krishnan Ramchandran, PhD ; Sossy Sahakian, BS ; Mark Hardy, MD ; Shanta Modak, PhD

594
In Vitro Potency of Rib-X Novel Compounds against Respiratory Pseudomonas aeruginosa isolates
Seth T. Housman, PharmD, MPA ; Christina Sutherland, BS ; David Nicolau, PharmD, FCCP, FIDSA

595
Prevalence of Arbekacin Resistance Genes Among Gram Negative Bacteria Isolated from Infected Patients in a Large Military Hospital 
Patrick Mc Gann, PhD ; Melissa Barber, AS, MLT (AMT) ; Glenn Wortmann, MD ; Paige Waterman, MD ; Michael Zapor, MD, PhD

597
In Vitro Activity of ACHN-490 Tested Against Gram-Negative and Gram-Positive Pathogens Isolated from Patients in Canadian Hospitals in 2011: CANWARD Surveillance Study
George G. Zhanel, PhD ; James Karlowsky, PhD ; Heather J. Adam, PhD ; Melanie Baxter, MSc ; Andrew Walkty, MD ; Philippe Lagacé-Wiens ; Frank Schweizer, PhD ; Daryl J. Hoban, PhD

598
Activity of JNJ-Q2 and Comparators against Genetically Defined MRSA Clones
David J. Farrell, Ph.D. ; Lisa C. Liverman ; Rodrigo E. Mendes, Ph.D. ; Douglas Biedenbach, BS, MT ; Ronald Jones, MD

600
In vitro and ex-vivo antimicrobial activity of PMX30063-a novel mimic of host defense proteins (HDP)
Bozena Korczak, PhD ; Richard Scott, PhD ; Daniel F. Sahm, Ph.D. ; Chris Pillar

602
Efficacies  of Vancomycin, Tigecycline alone and the combination of Tigecycline plus Daptomycin on Multi-Drug Resistant Organism Induced War Wound Rabbit Osteomyelitis Model
Li-Yan Yin, MD ; Jason Calhoun, MD ; M.M. Manring, PhD ; Ian Skinner ; Paul Hutchinson ; Randy Roberts ; Yi Ding ; Gan Tong ; Clinton K. Murray, MD

603
Pharmacokinetics, Safety and Tolerability of a Novel Fluorocycline, TP-434, Following Multiple Dose Oral Administration With and Without Food
Patrick T Horn, MD, PhD ; Joyce A Sutcliffe, PhD ; Susannah Walpole, PhD ; Anton Leighton, MD

604
Evaluation of Occurrence and Resistance Mechanisms of Pleuromutilins in Staphylococcus aureus Clinical Isolates: Report from the SENTRY Antimicrobial Surveillance Program
Rodrigo E. Mendes, Ph.D. ; Andrew Costello ; Lalitagauri M. Deshpande, Ph.D. ; Mariana Castanheira, PhD ; Ronald Jones, MD

606
Bacteriophage therapy of Staphylococcus aureus including MRSA
Sarah Kuhl, MD, PhD ; Greg Kearney, UCSD student

608
Antimicrobial efficacy of non-thermal plasma-treated alginate wound-dressing against multidrug resistant pathogens
Alexander Poor, MD ; Utku Ercan, BS ; Gregory Fridman, PhD ; Alexander Fridman, PhD ; Gary Friedman, PhD ; Ari Brooks, MD ; Suresh Joshi, MD, PhD

611
Intrapulmonary Penetration of CXA-201 and Piperacillin/tazobactam in Healthy Adult Subjects
Gurudatt Chandorkar, PhD ; Jennifer Huntington, PharmD ; Tara Parsons ; Mark Gotfried, MD ; Obiamiwe Umeh, MD, MSc

612
Activity of JNJ-Q2, a Novel Fluoroquinolone, Tested against Neisseria gonorrhoeae, Including Ciprofloxacin-Resistant Strains
Douglas Biedenbach, BS, MT ; J Almenoff ; Rachel Prochaska ; Ronald Jones, MD ; David J. Farrell, Ph.D.

CME Credits:

ACPE Credits:

ACPE Number:


Findings in the abstracts are embargoed until 12:01 a.m. EST Thursday, Oct. 20 with the exception of research findings presented at IDSA press conferences.